Fertility and sterility · 2013
Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Ming-Huei, Wu Frank Shao-Ying, Lee Robert Kuo-Kuang, Li Sheng-Hsiang, Lin Shyr-Yeu, Hwu Yuh-Ming
Аннотация
OBJECTIVE: To investigate whether dual triggering of final oocyte maturation with a combination of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) can improve the live-birth rate for normal responders in GnRH-antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI) cycles.
DESIGN: Retrospective cohort study.
SETTING: Infertility unit of a university-affiliated medical center.
PATIENT(S): Normal responders to controlled ovarian hyperstimulation who were undergoing IVF-ICSI with a GnRH antagonist protocol.
INTERVENTION(S): Standard dosage of hCG trigger (6,500 IU of recombinant hCG) versus dual trigger (0.2 mg of triptorelin and 6,500 IU of recombinant hCG).
MAIN OUTCOME MEASURE(S): Live-birth, clinical pregnancy, and implantation rates per cycle.
RESULT(S): A total of 376 patients with 378 completed cycles with embryo transfer were enrolled (hCG trigger/control group: n = 187; dual trigger/study group: n = 191). The dual trigger group demonstrated statistically significantly higher implantation (29.6% vs. 18.4%), clinical pregnancy (50.7% vs. 40.1%), and live-birth (41.3% vs. 30.4%) rates as compared with the hCG trigger group. There was no statistically significant difference in terms of patient demographics, cycle parameters, or embryo quality.
CONCLUSION(S): Dual trigger of final oocyte maturation with a GnRH-agonist and a standard dosage of hCG in normal responders statistically significantly improves implantation, clinical pregnancy, and live-birth rates in GnRH-antagonist IVF cycles.
DESIGN: Retrospective cohort study.
SETTING: Infertility unit of a university-affiliated medical center.
PATIENT(S): Normal responders to controlled ovarian hyperstimulation who were undergoing IVF-ICSI with a GnRH antagonist protocol.
INTERVENTION(S): Standard dosage of hCG trigger (6,500 IU of recombinant hCG) versus dual trigger (0.2 mg of triptorelin and 6,500 IU of recombinant hCG).
MAIN OUTCOME MEASURE(S): Live-birth, clinical pregnancy, and implantation rates per cycle.
RESULT(S): A total of 376 patients with 378 completed cycles with embryo transfer were enrolled (hCG trigger/control group: n = 187; dual trigger/study group: n = 191). The dual trigger group demonstrated statistically significantly higher implantation (29.6% vs. 18.4%), clinical pregnancy (50.7% vs. 40.1%), and live-birth (41.3% vs. 30.4%) rates as compared with the hCG trigger group. There was no statistically significant difference in terms of patient demographics, cycle parameters, or embryo quality.
CONCLUSION(S): Dual trigger of final oocyte maturation with a GnRH-agonist and a standard dosage of hCG in normal responders statistically significantly improves implantation, clinical pregnancy, and live-birth rates in GnRH-antagonist IVF cycles.
Предметные рубрики MeSH
Academic Medical CentersAdultChi-Square DistributionChorionic GonadotropinDrug Administration ScheduleDrug Therapy, CombinationEmbryo ImplantationEmbryo TransferFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHumansLive BirthOocyte RetrievalOvaryOvulationOvulation InductionPregnancyPregnancy RateRecombinant ProteinsRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeTriptorelin Pamoate